4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-amino}-piperidine-1-carboxylic Acid Tert-Butyl Ester | 607372-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-amino}-piperidine-1-carboxylic Acid Tert-Butyl Ester
• 英文别名: tert-butyl 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]methylamino]piperidine-1-carboxylate
• CAS: 607372-48-5
• 化学式: C₂₁H₃₀N₈O₃
• 分子量: 442.521
• InChiKey: CYTICGRHPDQMHS-UHFFFAOYSA-N

物化性质

• 沸点：
  655.8±65.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  137
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-amino}-piperidine-1-carboxylic Acid Tert-Butyl Ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以82%的产率得到SB 747651-A
  参考文献：
  名称：

  (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors

  摘要：

  The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases. (c) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2005.05.020
• 作为产物：
  描述：

  (3-溴-5-硝基-吡啶-4-基)-乙基-胺 在 盐酸 、 正丁基锂 、 sodium dithionite 、 (polystyrylmethyl)trimethylammonium cyanoborohydride 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 生成 4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ylmethyl]-amino}-piperidine-1-carboxylic Acid Tert-Butyl Ester
  参考文献：
  名称：

  (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors

  摘要：

  The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases. (c) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2005.05.020

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXO GROUP LTD

  公开号：WO2003080610A1

  公开（公告）日：2003-10-02

  A compound of the formula: (I) and-physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR.3; X2 is N or CR'4; X3 ,is..N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X 2, X,3. and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d formula: (II) wherein X5 is a group selected from N or CR7: and X6, is a group selected from O, S or NR8; X7 and X8; which maybe the same or, different is a group selected from N or CR9; ; X9, is a group selected from O, S or NR8 and X10 is N or CR10 ; X11 , X12 and X13 may be the same or different and selected from a group N or CR11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

  化合物的式子为：（I），其生理上可接受的盐和/或N-氧化物，其中，X1为N或CR.3；X2为N或CR'4；X3为N或CR5；X4为N或CR6，但至少其中一个但不超过两个X1、X2、X3和X4代表N。R1是从a、b、c或d组中选择的5-或6-成员杂环基，式子为：（II），其中X5是从N或CR7选择的基团；X6是从O、S或NR8选择的基团；X7和X8可以相同或不同，是从N或CR9选择的基团；X9是从O、S或NR8选择的基团，X10是N或CR10；X11、X12和X13可以相同或不同，是从N或CR11的基团中选择的；制备它们的过程，包含它们的制药组合物以及它们在医学上的用途。
• Imidazopyridine derivatives as kinase inhibitors
  申请人：Bailey Nicholas

  公开号：US20050197328A1

  公开（公告）日：2005-09-08

  A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X 1 is N or CR 3 ; X 2 is N or CR 4 ; X 3 is N or CR 5 ; X 4 is N or CR 6 . with the proviso that at least one but not more than two of X 1 , X 2 , X 3 and X 4 represents N. R 1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X 5 is a group selected from N or CR 7 and X 6 is a group selected from O, S or NR 8; X 7 and X 8 which may be the same or different is a group selected from N or CR 9; X 9 is a group selected from O, S or NR 8 and X 10 is N or CR 10; X 11 , X 12 and X 13 may be the same or different and selected from a group N or CR 11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

  式中化合物及其生理上可接受的盐和/或N-氧化物，其中： X1为N或CR3； X2为N或CR4； X3为N或CR5； X4为N或CR6； 但须满足X1、X2、X3和X4中至少一个但不超过两个为N； R1为从a、b、c或d组中选择的5-或6-成员杂环基，其中X5为N或CR7组，X6为O、S或NR8组； X7和X8可以相同或不同，为N或CR9组； X9为O、S或NR8组，X10为N或CR10组； X11、X12和X13可以相同或不同，为N或CR11组； 本发明还涉及其制备方法、包含它们的制药组合物以及它们在医学上的应用。
• IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1490367A1

  公开（公告）日：2004-12-29
• US7348339B2
  申请人：——

  公开号：US7348339B2

  公开（公告）日：2008-03-25
• (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors
  作者：Mark J. Bamford、Nicholas Bailey、Susannah Davies、David K. Dean、Leann Francis、Terence A. Panchal、Christopher A. Parr、Sanjeet Sehmi、Jon G. Steadman、Andrew K. Takle、James T. Townsend、David M. Wilson

  DOI：10.1016/j.bmcl.2005.05.020

  日期：2005.7

  The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases. (c) 2005 Published by Elsevier Ltd.